Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma Patients

11 Apr 2020

Abstract excerpt

Resistance is a major challenge in the management of mitogen-activated protein kinase inhibitor (MAPKi)-treated metastatic melanoma. Tumor genetic alterations can cause MAPK pathway reactivation, leading to lack of response and poor outcome. Characterization of the mutational profile in patients with melanoma might be crucial for patient-tailored treatment choices. Mutations in the promoter region of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Mechanics and Interactions
Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32290374
DOI: 10.3390/cancers12040946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma PatientsPMID 32290374Read ↗

TERT promoter mutation subtypes and survival in stage I and II melanoma patients.Semantic proximity Read ↗

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.Semantic proximity Read ↗

TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated MelanomaSemantic proximity Read ↗

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.Semantic proximity Read ↗

Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort.Semantic proximity Read ↗

<scp><i>TERT</i></scp> promoter mutations in melanoma survivalSemantic proximity Read ↗

TERT Promoter Mutations and Telomerase in MelanomaSemantic proximity Read ↗

TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.Semantic proximity Read ↗

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In VitroSemantic proximity Read ↗

TERT mutations in Malignant Melanoma-Survival Meta-AnalysisSemantic proximity Read ↗

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.Semantic proximity Read ↗

TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.